In this episode, learn how early and sustained HBV care can be enhanced by expanding the role of primary care providers in HBV management. Learn how to:
- Engage key stakeholders in the provision of HBV care
- Provide HBV management resources to support PCPs who are doing screening
- Consider specialty and primary care collaborations that empower PCPs with clear guidance on how to manage patients living with HBV
Presenters:
Su Wang, MD, MPH, FACP
Medical Director
Center for Asian Health and Viral Hepatitis Programs
Cooperman Barnabas Medical Center
RWJBarnabas-Rutgers Medical Group
Associate Member
Health Care Policy and Aging Research
The Rutgers Institute for Health
Senior Advisor
Global Health, Hepatitis B Foundation
Florham Park, New Jersey
Richard R. Andrews, MD, MPH
President, Houston Viral Hepatitis Task Force
Former Co-Chair, National Task Force on Hepatitis B
Board-Certified Family Medicine
Addiction Medicine Physician
Houston, Texas
Ruth Brogden, MPH
Patient Advocate
Amy S. Tang, MD
Former Co-Chair, National Task Force on Hepatitis B
Director of Immigrant Health
North East Medical Services
San Francisco, California
Link to full program:
https://bit.ly/3TuqFHI
Link to the slides:
https://bit.ly/44hXpHu
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
In this episode, Mark S. Sulkowski, MD, FIDSA, FAASLD; Tatyana Kushner, MD, MSCE; Paul Y. Kwo, MD; and patient advocate Jacki Chen, PhD, consider barriers and solutions for more expansive HBV treatment in the United States. Topics include:
- Patient subgroups to consider for treatment outside guideline criteria
- Adverse event and cost-effectiveness considerations
- Integration of patient perspectives in wider treatment
Presenters:
Mark S. Sulkowski, MD, FIDSA, FAASLD
Professor of Medicine
Director, Division of Infectious Diseases, Johns Hopkins Bayview Medical Center
Johns Hopkins University School of Medicine
Baltimore, Maryland
Tatyana Kushner, MD, MSCE
Associate Professor
Division of Liver Diseases
Icahn School of Medicine at Mount Sinai
New York, New York
Paul Y. Kwo, MD
Professor of Medicine
Director of Hepatology
Stanford University School of Medicine
Palo Alto, California
Jacki Chen, PhD
Patient Advocate
Link to full program:
https://bit.ly/3TuqFHI
Link to the slides:
https://bit.ly/4a60GM4
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
In this episode, Arun B. Jesudian, MD, and Mazen Noureddin, MD, MHSc, discuss the expert-informed clinical pathway for the multidisciplinary care of patients with MASLD or MASH, current and emerging therapeutics, and management optimization strategies.
Presenters:
Arun B. Jesudian, MD
Associate Professor of Clinical Medicine
Division of Gastroenterology and Hepatology
Weill Cornell Medicine
New York, New York
Mazen Noureddin, MD, MHSc
Professor of Medicine
Houston Methodist Hospital
Director
Houston Research Institute
Houston, Texas
Content based on an online CME program supported by independent educational grants from Novo Nordisk.
To view the full program on “Clinical Pathways: Multidisciplinary Approach to Managing Metabolic Dysfunction‒Associated Steatohepatitis,” including 4 CME/CE-certified text modules with accompanying slidesets, 4 ClincalThought commentaries, and a downloadable infographic resource on the AGA MASLD MASH Clinical Care Pathway, visit clinicaloptions.com or click on the link below.
Link to full program:
https://bit.ly/3Tyu7At
In this episode, Douglas Dieterich, MD, leads a panel discussion with Camilla S. Graham, MD, MPH, and Robert Wong, MD, MS, to consider advantages and barriers to universal screening for chronic HBV infection and universal HDV screening in adults with HBV in the United States. Topics include:
- Updated CDC recommendations for one-time universal screening for HBV
- Addressing patient-, provider-, and system-level barriers to universal HBV screening
- Best practices for implementation of HDV screening
Presenters:
Douglas Dieterich, MD
Director, Institute for Liver Medicine
Professor of Medicine
Division of Liver Diseases
Mount Sinai School of Medicine
New York, New York
Camilla S. Graham, MD, MPH
Co-Director, Viral Hepatitis Clinic
Division of Infectious Diseases
Beth Israel Deaconess Medical Center
Harvard Medical School
Boston, Massachusetts
Robert Wong, MD, MS
Clinical Associate Professor
Division of Gastroenterology and Hepatology
Stanford University School of Medicine
Palo Alto, California
Link to full program:
https://bit.ly/3TuqFHI
Link to the slides:
https://bit.ly/4atS42z
In this episode, Renslow Sherer, MD, and Trinh P. Vu, PharmD, BCIDP, discuss strategies for managing ambulatory patients with acute or previous COVID-19 infection, including:
- Current COVID-19 landscape
- Rapid antigen tests and PCR tests
- Risk stratification of patients who have a positive SARS-CoV-2 test
- Antiviral treatment (nirmatrelvir + ritonavir, remdesivir, and molnupiravir)
- Long COVID
Presenters:
Renslow Sherer, MD
Director, International HIV Training Center
Professor of Medicine
Section of Infectious Diseases and Global Health
Department of Medicine
University of Chicago
Chicago, Illinois
Trinh P. Vu, PharmD, BCIDP
Clinical Pharmacy Specialist in Infectious Diseases
Department of Pharmaceutical Services
Emory University Hospital Midtown
Atlanta, Georgia
To download the slides: bit.ly/3oHKC09
To view the full online program: bit.ly/4201xcO
In this episode, Jona Tanguay, MMSc, PA-C, AAHIVS discusses considerations to review with patients to empower them to make their own informed choices in PrEP selection, including:
- Leveraging PrEP options with unique dosing schedules and/or routes such as long-acting cabotegravir and on-demand 2-1-1 FTC/TDF
- Differences in adverse effect profiles between 4 PrEP options
- Potential for HIV resistance
- Requirements for compliance and monitoring
- Evidence in populations with various acquisition behaviors
- Drug interaction implications
Faculty:
Jona Tanguay, MMSc, PA-C, AAHIVS
Health Care Provider and HIV Specialist
Whitman-Walker Health
Vice President for Education, GLMA: Health Professionals Advancing LGBTQ Equality
Clinical Instructor, Yale University School of Nursing
Washington, DC
Link to full program: https://bit.ly/41WF54o
In this episode, Dr. Parsons and Dr. Battista discuss current and emerging medical therapies for the treatment of spinal muscular atrophy (SMA). They review safety, efficacy, and monitoring parameters of current agents, as well as adjuct therapies in the medication pipeline. This high-level overview includes:
- Review of FDA-approved medical therapies: nusinersen, onasemnogene abeparvovec-xioi, and risdiplam
- Discussion of the safety, efficacy, and monitoring parameters for FDA approved medications, as well as adjuctive agents for medication therapy complications
- Review of ongoing clinical trials on anti-myostatin medications and discussion of the role these agents would play if approved by the FDA
Presenters:
Julie Parsons, MD
Co-Director, Neuromuscular Clinic
Haberfeld Family Endowed Chair in Pediatric Neuromuscular Disorders
Professor of Clinical Pediatrics and Neurology
Children’s Hospital Colorado
Denver, Colorado
Vanessa Battista, DNP, MBA, RN, MS, CPNP-PC, CHPPN, FPCN
Senior Director of Nursing, Palliative Care
Psychosocial Oncology and Palliative Care
Dana-Farber Cancer Institute
Boston, Massachusetts
Supported by an educational grant from Biogen
Link to full program:
bit.ly/41kw2dK
Link to CME: Claim credit -
bit.ly/40fkDKD
In this episode, Dr. Battista and Dr. Parsons discuss the importance of care guidelines and the multidisciplinary team in the treatment of spinal muscular atrophy (SMA). This overview will include:
- The role each member of the interdisciplinary team plays in the care of SMA including physical therapists, occupational therapists, and speech therapists
- The importance of continued, ongoing therapy in addition to medication therapy to provide the greatest improvement in SMA care
- How to manage transitions in care, including the transition from pediatrics to adulthood and how to include the necessary support teams
- The role shared decision-making plays in the treatment of patients with SMA
Presenters:
Julie Parsons, MD
Co-Director, Neuromuscular Clinic
Haberfeld Family Endowed Chair in Pediatric Neuromuscular Disorders
Professor of Clinical Pediatrics and Neurology
Children’s Hospital Colorado
Denver, Colorado
Vanessa Battista, DNP, MBA, RN, MS, CPNP-PC, CHPPN, FPCN
Senior Director of Nursing, Palliative Care
Psychosocial Oncology and Palliative Care
Dana-Farber Cancer Institute
Boston, Massachusetts
Supported by an educational grant from Biogen.
Link to full program:
https://bit.ly/43Dmo7q
Link to CME: Claim credit
https://bit.ly/40gulfX
In this episode, Julie Parsons, MD, discusses the genetic diagnosis of spinal muscular atrophy (SMA), anticipated clinical findings, the importance of newborn screenings, and the next steps to consider after a positive diagnosis is obtained. This high-level overview includes:
- SMA as an autosomal recessive disease
- Differences in spinal motor neurons (SMN) 1 and 2 at the time of diagnosis and how these drive severity of disease
- Important clinical findings in the diagnosis of SMA, as every child may not be identified with newborn screening
- The importance of newborn screening and critical next steps and logistical considerations when receiving a positive screen in your practice
Presenters:
Julie Parsons, MD
Co-Director, Neuromuscular Clinic
Haberfeld Family Endowed Chair in Pediatric Neuromuscular Disorders
Professor of Clinical Pediatrics and Neurology
Children’s Hospital Colorado
Denver, Colorado
Vanessa Battista, DNP, MBA, RN, MS, CPNP-PC, CHPPN, FPCN
Senior Director of Nursing, Palliative Care
Psychosocial Oncology and Palliative Care
Dana-Farber Cancer Institute
Boston, Massachusetts
Supported by an educational grant from Biogen
Link to full program:
bit.ly/41kw2dK
Link to CME: Claim credit -
bit.ly/40eyBwr
In this episode, Vikramjit Mukherjee, MD, and Cameron Smith, MPAS, PA-C, answer audience questions on how best to care for hospitalized patients with COVID-19 from a live, virtual question and answer webinar. This episode includes expert insights on:
- Viral coinfections such as influenza and RSV
- New data comparing baricitinib and tocilizumab for patients with severe COVID-19
- Management of bacterial and fungal coinfection while incorporating antimicrobial stewardship
- Tips for transitioning patients out of the ICU and to the medical floor or home
Presenters:
Vikramjit Mukherjee, MD
Assistant Professor
Division of Pulmonary, Critical Care, & Sleep Medicine
New York University School of Medicine
Director
Medical Intensive Care Unit
Bellevue Hospital
New York
Cameron Smith MPAS, PA-C
Lead Advanced Practice Provider
Medical Intensive Care Unit
Bellevue Hospital
New York Health and Hospitals
New York
Content based on an online program supported by an independent educational grant from Gilead Sciences, Inc. Link to full program:
bit.ly/3z52c00
In this episode, Vikramjit Mukherjee, MD, and Cameron Smith, MPAS, PA-C, answer audience questions on how best to care for hospitalized patients with COVID-19 from a live, virtual question and answer webinar. This episode includes expert insights on:
- Supportive care management such as oxygen support, glycemic control, and anticoagulation
- Escalation of therapy in patients with worsening oxygen requirements
- Use of remdesivir in patients with renal dysfunction
- Brief commentary on long COVID
Presenters:
Vikramjit Mukherjee, MD
Assistant Professor
Division of Pulmonary, Critical Care, & Sleep Medicine
New York University School of Medicine
Director
Medical Intensive Care Unit
Bellevue Hospital
New York
Cameron Smith MPAS, PA-C
Lead Advanced Practice Provider
Medical Intensive Care Unit
Bellevue Hospital
New York Health and Hospitals
New York, New York
Content based on an online program supported by an independent educational grant from Gilead Sciences, Inc.
bit.ly/3z52c00
In this podcast, Susan LeLacheur, DrPH, PA-C, AAHIVS discusses racial disparities in access to HIV prevention (PrEP) and strategies to close these gaps, including:
- Incorporating comprehensive sexual history into medical appointments and offering PrEP to all sexually active patients
- Increase awareness of PrEP access programs in communities of color
- Diversification of the medical workforce
Faculty:
Susan LeLacheur, DrPH, PA-C, AAHIVS
Professor
Department of Physician Assistant Studies
School of Medicine and Health Sciences
The George Washington University
Washington, DC
Link to full program: https://practicingclinicians.com/content/hiv-prevention-resource-center
This podcast episode is part of a multimedia program reviewing the management of nontuberculous mycobacterial lung disease (NTM-LD). Tune in to hear Jennifer Faber-Gerling, RN, MS, CNS, ANP-BC, and Anne O’Donnell, MD, highlight the diagnostic criteria and optimal treatment strategies in patients with NTM-LD. The overview will include:
- Recommended assessments and tests to appropriately diagnosis NTM-LD in patients
- A summary of the current guidelines for the management of NTM-LD, including appropriate monitoring of medications.
- Guidance on how to individualize treatment plans for patients with NTM-LD based on disease and patient characteristics
Presenters:
Jennifer Faber-Gerling, RN, MS, CNS, ANP-BC
Nurse Practitioner
Division of Mycobacterial and Respiratory Infections
National Jewish Health
Denver, Colorado
Anne O’Donnell, MD
Professor of Medicine
Division of Pulmonary, Critical Care, and Sleep Medicine
Georgetown University Medical Center
Washington, DC
To view other program offerings, including a CE-certified on-demand webcast, a Q&A text module, and to download slides, visit
pce.is/NTM.
In this episode, Tracy Zivin-Tutela, MD, answers audience questions on how best to care for patients at high risk of complications due to influenza from a live virtual meeting series. This episode includes expert insights on:
- Emerging resistance patterns of currently used antivirals
- Getting the flu vaccine after treatment with antivirals
- Use of antivirals in patients who test positive for flu and COVID-19
- Techniques and over-the-counter therapies other than yearly vaccination to avoid severe complications due to the flu
- Avoiding dairy after receiving baloxavir
- Insurance coverage for antivirals
- Considering bacterial and viral coinfection in patients with lung disease
- Retreating high-risk patients with antivirals after another flu exposure
- Calculating flu rates
Presenter:
Tracy Zivin-Tutela, MD
Attending Physician
Division of Infectious Diseases
Department of Medicine
Los Alamitos Medical Center, Fountain Valley Regional Hospital
New Brunswick, California
Daniel Zalinov, PA-C
Atrium Health
Charlotte, North Carolina
Link to full program:
https://bit.ly/3GMokRC
In this episode, Stephen Krieger, MD, and Allison Boyd, MPAS, PA-C, MSCSdiscuss the expanding treatment armamentarium for MS, the complexities involved in making treatment selection, patient factors to consider when individualizing treatment, and how best to talk with patients about their options within the context of shared decision-making.
Stephen Krieger, MD: consultant/advisor/speaker: Biogen, EMD Serono, Genentech, Genzyme/Sanofi, Novartis, Octave, TG Therapeutics; researcher: Biogen, Bristol-Myers Squibb, Novartis, Sanofi.
Allison L. Boyd, MPAS, PA-C, MSCS: consultant/advisor/speaker: EMD Serono.
In this episode, Stephen Krieger, MD, and Allison Boyd, MPAS, PA-C, MSCSdiscuss timely recognition of MS, including insights into why early recognition can lead to early treatment, which can decrease the risk of disability progression and produces better outcomes. Challenges discussed include the variable clinical presentation of MS and the lack of specific tests. The experts also discuss how to avoid missed diagnosis and misdiagnosis.
Stephen Krieger, MD: consultant/advisor/speaker: Biogen, EMD Serono, Genentech, Genzyme/Sanofi, Novartis, Octave, TG Therapeutics; researcher: Biogen, Bristol-Myers Squibb, Novartis, Sanofi.
Allison L. Boyd, MPAS, PA-C, MSCS: consultant/advisor/speaker: EMD Serono.
In this episode, Stephen Krieger, MD, and Allison Boyd, MPAS, PA-C, MSCS discuss the challenges of managing patients with MS over the long-term, including assessment and management of comorbidities management, differentiating relapse from pseudorelapse, telemedicine, and the important role of NPs and PAs in multidisciplinary care.
In this podcast, Latesha Elopre, MD, MSPH, discusses how the new CDC recommendations on pre-exposure prophylaxis (PrEP) education, eligibility, and monitoring affect her clinical practice.
Contributors:
Latesha Elopre, MD, MSPH
Associate Professor
Division of Infectious Diseases
University of Alabama at Birmingham
Birmingham, Alabama
Latesha Elopre, MD, MSPH, has no relevant financial relationships to disclose.
In this podcast, Latesha Elopre, MD, MSPH and Jason Farley, PhD, MPH, ANP-BC, FAAN, AACRN answer pressing questions from healthcare professionals who care for patients that may be at risk for HIV infection.
Presenters:
Latesha Elopre, MD, MSPH
Associate Professor
Division of Infectious Diseases
University of Alabama at Birmingham
Birmingham, Alabama
Moderator
Jason Farley, PhD, MPH, ANP-BC, FAAN AACRN
Endowed Professor of Nursing Leadership and Innovation
Johns Hopkins University School of Nursing
Director, Center for Infectious Disease and Nursing Innovation
Adult Nurse Practitioner, Infectious Diseases
Johns Hopkins Medicine
Baltimore, Maryland
In this podcast, Latesha Elopre, MD, MSPH discusses options for pre-exposure prophylaxis (PrEP). Listen as she explains best practices for the nonpharmacologic prevention of HIV, as well as oral and injectable pharmacologic PrEP options.
Presenters:
Latesha Elopre, MD, MSPH
Associate Professor
Division of Infectious Diseases
University of Alabama at Birmingham
Birmingham, Alabama
Moderator
Jason Farley, PhD, MPH, ANP-BC, FAAN, AACRN
Endowed Professor of Nursing Leadership and Innovation
Johns Hopkins University School of Nursing
Director, Center for Infectious Disease and Nursing Innovation
Adult Nurse Practitioner, Infectious Diseases
Johns Hopkins Medicine
Baltimore, Maryland
In this podcast, Latesha Elopre, MD, MSPH discusses the new CDC guideline recommendations for pre-exposure prophylaxis (PrEP). Listen as she explains the updated eligibility criteria, assessing indications for PrEP, and best practices for HIV/antibody testing.
Presenter:
Latesha Elopre, MD, MSPH
Associate Professor
Division of Infectious Diseases
University of Alabama at Birmingham
Birmingham, Alabama
Moderator
Jason Farley, PhD, MPH, ANP-BC, FAAN AACRN
Endowed Professor of Nursing Leadership and Innovation
Johns Hopkins University School of Nursing
Director, Center for Infectious Disease and Nursing Innovation
Adult Nurse Practitioner, Infectious Diseases
Johns Hopkins Medicine
Baltimore, Maryland
In this podcast, Latesha Elopre, MD, MSPH discusses inequities in pre-exposure prophylaxis (PrEP) uptake and the importance of sexual health screening. Additionally, Dr Elopre shares her best practices for receiving an adequate sexual health history from her patients.
Presenters:
Latesha Elopre, MD, MSPH
Associate Professor
Division of Infectious Diseases
University of Alabama at Birmingham
Birmingham, Alabama
Moderator
Jason Farley, PhD, MPH, ANP-BC, FAAN AACRN
Endowed Professor of Nursing Leadership and Innovation
Johns Hopkins University School of Nursing
Director, Center for Infectious Disease and Nursing Innovation
Adult Nurse Practitioner, Infectious Diseases
Johns Hopkins Medicine
Baltimore, Maryland
This podcast episode is part of a multimedia program discussing the co-management of moderate to severe atopic dermatitis (AD) in the primary care and specialty settings. Tune in to hear Dr Silverberg and NP Victoria Garcia-Albea highlight newly approved agents and the recent expanded labeling of an existing AD therapy, including:
- Ruxolitinib, a topical JAK inhibitor for mild to moderate AD approved in 2021
- Abrocitinib and upadacitinib, oral JAK inhibitors approved in early 2022 for moderate to severe AD
- Tralokinumab, an IL-13 inhibitor available as a subcutaneous injection, which was approved in late 2021 for moderate to severe AD
- Expanded approval for use in patients as young as 6 months for dupilumab, a subcutaneous IL-4 receptor α inhibitor
Presenters:
Jonathan Silverberg, MD, PhD, MPH
Associate Professor
Director of Clinical Research
Director of Patch Testing
George Washington University School of Medicine and Health Sciences
Washington, DC
Victoria Garcia-Albea, PNP, DCNP, MSN, BSN, PRN
Director
Lahey Dermatology Nurse Practitioner Training Program
Lahey Hospital and Medical Center
Burlington, Massachusetts
To view other program offerings, including a CE-certified recorded roundtable webcast, a ClinicalThought commentary, and to download slides, visit:
https://bit.ly/3PiupXZ
In this episode, John M. Burke, MD, a leading expert, and Amy Esposito, FNP-C provide expert insights on key data presented at the 2022 ASCO annual conference for CLL/SLL regarding:
- Updated response and safety results after 3 years of follow-up from the phase II CAPTIVATE study of ibrutinib and venetoclax in patients with previously untreated CLL
- Updated response and remission rates after 4 years of follow-up from a phase II trial of obinutuzumab, ibrutinib, and venetoclax in patients with either treatment-naïve or relapsed/refractory CLL
- Progression free survival and safety results after 5 years of follow-up from the ELEVATE-TN phase III study of Acalabrutinib ± Obinutuzumab vs
Obinutuzumab + Chlorambucil as first-line therapy in CLL - Assessments of whether racial and/or ethnic identity, and socioeconomic status are prognostic factors of survival in CLL
Presenter
John M. Burke, MD
Rocky Mountain Cancer Centers
Aurora, Colorado
Moderator
Amy Esposito, FNP-C
Nurse Practitioner
Rocky Mountain Cancer Center
Aurora, Colorado
In this episode, Tycel J. Phillips, MD, and Amy Goodrich, RN, MSN, CRNP-AC, provide expert insights on key data presented at ASCO 2022 for mantle cell lymphoma regarding:
- Results from the phase III SHINE study of the addition of ibrutinib the first-line BR followed by rituximab maintenance in older patients with MCL
- Updated results from the phase II ZUMA-2 study evaluating brexucabtagene autoleucel for patients with R/R MCL
- Results from a phase I/II study of the ROR1 humanized monoclonal antibody, zilovertamab, in combination with ibrutinib for patients with R/R MCL, MZL, or CLL/SLL
- Preliminary results from a phase I study of the humanized ROR1xCD3 bispecific antibody, NVG-111, in R/R CLL and MCL after ≥2 previous therapies
Presenters:
Tycel J. Phillips, MD
Maria Reinhardt Decesare Research Professor of Blood Cancers and Bone Marrow Transplantation
Associate Professor of Medicine
University of Michigan
Rogel Cancer Center
Ann Arbor, Michigan
Amy Goodrich, RN, MSN, CRNP-AC
Research Associate, Department of Medicine
Johns Hopkins University
Nurse Practitioner, Department of Medicine
The Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland
Content supported by educational grants from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Link to full program, including a downloadable highlights slideset:
https://bit.ly/3yufCU4
In this episode, Sandip Patel, MD shares his thoughts on optimizing immune checkpoint inhibitor (ICI) therapy in advanced non-small-cell lung cancer (NSCLC) and discusses best practices for individualizing therapy decisions and managing adverse events.
Topics include:
- Currently approved ICIs
- Role of biomarker and PD-L1 testing in advanced NSCLC
- Strategies to individualize ICI treatment for patients with advanced NSCLC
- Strategies for identifying and managing immune-related adverse events in patients treated with ICI
Presenter:
Sandip P. Patel, MD
Associate Professor
Department of Medicine
Division of Hematology/Oncology
University of California – San Diego
La Jolla, California
Link to full program:
https://bit.ly/39vuCHC
In this episode, Brenda Martone, MSN, ANP-BC, AOCNP describes recent evidence on PARP inhibitor therapy in metastatic castrate-resistant prostate cancer (mCRPC) and discusses best practices for incorporating PARP inhibitors into clinical practice. Topics include:
- An overview of the PROpel study of olaparib and the TRITON study of rucaparib
- FDA-approved indications for olaparib and rucaparib
- Genetic and molecular testing for BRCA1/2 and other HRR mutations
- Managing adverse events associated with olaparib and rucaparib
- Monitoring for and managing anemia
- Gastrointestinal side effects
- Fatigue
- A look at the future of PARP inhibitors in mCRPC with combination approaches of AR-directed therapy and PARP inhibition
Presenter:
Brenda Martone, MSN, ANP-BC, AOCNP
Nurse Practitioner
Division of Genitourinary Oncology
Northwestern Medicine
Chicago, Illinois
Link to full program:
PCE.is/Onc22
In this episode, Julia LaBarbera, MSN, RN, AGACNP-BC, discusses the latest evidence and guidance on how advanced practice providers can optimize patient outcomes with CDK4/6 inhibitors for HR+/HER2- breast cancer. Topics include:
- An overview of the monarchE study leading to FDA approval of adjuvant abemaciclib
- Key trial data on abemaciclib, palbociclib, and ribociclib for metastatic HR+/HER2- breast cancer
- Managing adverse events associated with CDK4/6 inhibitors
- Promoting adherence to oral therapy
Presenter:
Julia LaBarbera, MSN, RN, AGACNP-BC
Nurse Practitioner
Division of Hematology/Oncology
Department of Medicine
University of California, Los Angeles
Santa Monica, California
Link to full program:
PCE.is/Onc22
In this episode, Beth Sandy, MSN, CRNP provides her thoughts on key data presented at the 2022 ASCO annual conference relating to immune checkpoint inhibitors in non-small cell lung cancer (NSCLC). Findings covered include:
- Survival results after 3 years from the phase III Checkmate 9LA study of nivolumab and ipilimumab combined with 2 cycles of chemotherapy vs chemotherapy in previously untreated advanced NSCLC
- Updated survival and safety results after 5 years from the phase III Checkmate 227 study of nivolumab and ipilimumab vs chemotherapy in previously untreated advanced NSCLC, including assessment of a treatment-free interval
- Updated analysis from the phase III ATEZO-BRAIN trial of atezolizumab + carboplatin and pemetrexed in patients with advanced NSCLC with untreated brain metastases
- Updated overall response analysis from the phase II KEYNOTE-799 study of pembrolizumab with concurrent chemoradiation in unresectable, locally advanced stage III NSCLC
- Results from a phase II trial evaluating nivolumab plus ipilimumab vs nivolumab monotherapy following chemoradiation in unresectable stage III NSCLC
- Pathological complete response results from the phase II NADIM II study of nivolumab and chemotherapy vs chemotherapy in the neoadjuvant NSCLC setting
Presenter:
Beth Sandy, MSN, CRNP
Nurse Practitioner
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania
Link to full program:
https://bit.ly/39vuCHC
In this episode, David S. Kountz, MD, discusses with Keith C. Ferdinand MD, FACC, FAHA, a patient case in which health disparities affected NVAF care and provides patient, provider, and health-system level strategies to address these disparities to improve NVAF-related cardiovascular outcomes.
Presenters
Keith C. Ferdinand, MD, FACC, FAHA
Professor of Medicine
Tulane Heart and Vascular Institute
Tulane University School of Medicine
New Orleans, Louisiana
David S. Kountz, MD
Professor of Medicine
Department of Medicine
Hackensack Meridian School of Medicine
Nutley, New Jersey
Link to full program:
https://bit.ly/3xn238i
In this episode, Keith C. Ferdinand MD, FACC, FAHA, discusses with David S. Kountz, MD, a patient case in which health disparities affected NVAF care and provides strategies to address low health literacy and patient access to direct-acting oral anticoagulant to improve NVAF-related cardiovascular outcomes.
Presenters
Keith C. Ferdinand, MD, FACC, FAHA
Professor of Medicine
Tulane Heart and Vascular Institute
Tulane University School of Medicine
New Orleans, Louisiana
David S. Kountz, MD
Professor of Medicine
Department of Medicine
Hackensack Meridian School of Medicine
Nutley, New Jersey
Link to full program:
https://bit.ly/3xn238i
In this podcast episode, 2 migraine experts discuss clinical pearls for individualizing migraine care from diagnosis to ongoing management. They cover patient factors to consider in the differential diagnosis, when choosing an acute treatment, and in making the decision to initiate preventive treatment. This activity is available for CE/CME credit. Claim your credit at pce.is/migraine.
Contributors
Maureen Moriarty, DNP, ANP-BC
Associate Professor
Director
Malek School of Nursing Professions
Marymount University
Arlington, Virginia
Owner
Moriarty Associates
Westminster, Maryland
Dr Moriarty:consultant/advisor/speaker: AbbVie/Allergan, Amgen, Biohaven, Lilly;researcher: Teva.
Karen A. Williams, DNP, FNP-BC, AQH
President
KDW Health Management
Pensacola, Florida
Dr Williams: consultant/advisor/speaker: Biohaven.
This podcast is the first in a series of 3 featuring an multidisciplinary panel of expert faculty addressing the impact of social determinants of health on NVAF and CV-related outcomes and strategies to overcome these disparities. In this episode, David S. Kountz, MD, provides a detailed explanation of the atrial fibrillation paradox and data on the impacts of SDOH on NVAF CV-related outcomes.Review the downloadable slideset and full program at: PCE.is/NVAF.
Contributors:
Program Director
Keith C. Ferdinand, MD, FACC, FAHA,has disclosed that he has received consulting fees from Amgen, Boehringer Ingelheim, Medtronic, Novartis, and Sanofi.
Faculty
David S. Kountz, MD, has no relevant conflicts of interest to report.
Laura Ross, PA-C, CLS, has no relevant conflicts of interest to report.
This podcast is the third in a series of 3 featuring an expert multidisciplinary panel of faculty addressing the impact of social determinants of health on NVAF and CV-related outcomes and strategies to overcome these disparities. In this episode, Keith C. Ferdinand, MD, FACC, FAHA, details the effects of SDOH on anticoagulation prescribing in NVAF and provides an overview of areas for future study. Review the downloadable slideset and full program at: PCE.is/NVAF.
Contributors:
Program Director
Keith C. Ferdinand, MD, FACC, FAHA, has disclosed that he has received consulting fees from Amgen, Boehringer Ingelheim, Medtronic, Novartis, and Sanofi.
Faculty
David S. Kountz, MD, has no relevant conflicts of interest to report.
Laura Ross, PA-C, CLS, has no relevant conflicts of interest to report.
This podcast is the second in a series of 3 featuring an expert multidisciplinary panel of faculty addressing the impact of social determinants of health on NVAF and CV-related outcomes and strategies to overcome these disparities. In this episode, Laura Ross PA-C, CLS, dives deeper into the impacts of SODH on NVAF care and provides strategies to address to improve patient care and clinical outcomes in NVAF. Review the downloadable slideset and full program at: PCE.is/NVAF.
Contributors:
Program Director
Keith C. Ferdinand, MD, FACC, FAHA, has disclosed that he has received consulting fees from Amgen, Boehringer Ingelheim, Medtronic, Novartis, and Sanofi.
Faculty
David S. Kountz, MD, has no relevant conflicts of interest to report.
Laura Ross, PA-C, CLS, has no relevant conflicts of interest to report.
This podcast is the first in a series of four featuring IBD specialists Drs Anita Afzali, MD, MPH, FACG, AGAF and Nana Bernasko, DNP, CRNP, WHNP-BC. In this episode, the experts discuss the importance early and accurate diagnosis and classification of IBD plays in choosing appropriate and individualized therapies for disease management.
Presenters:
Anita Afzali, MD, MPH, FACG, AGAF
Professor of Clinical Medicine
Abercrombie & Fitch Endowed Chair in Inflammatory Bowel Disease
Medical Director, OSU Inflammatory Bowel Disease Center
Program Director, Advanced Inflammatory Bowel Disease Fellowship
Division of Gastroenterology, Hepatology, and Nutrition
The Ohio State University Wexner Medical Center
Columbus, Ohio
Nana Bernasko, DNP, CRNP, WHNP-BC
Assistant Professor
Division of Gastroenterology and Hepatology
Department of Medicine
Penn State University Medical Center
Hershey, Pennsylvania
The content in this series was adapted from a live CE program supported by educational grants from Amgen, Ferring Pharmaceuticls, Inc., and the Leona M. and Harry B. Helmsley Charitable Trust.
To access the full program, go to
pce.is/IBD
This podcast is the second in a series of four featuring IBD specialists Drs Anita Afzali, MD, MPH, FACG, AGAF and Nana Bernasko, DNP, CRNP, WHNP-BC. Our moderator for the series is Mr Rick Davis, PA-C. In this episode, our panel of experts review available medication options and their current place in therapy according to recent evidence and guideline recommendations.
Presenters:
Anita Afzali, MD, MPH, FACG, AGAF
Professor of Clinical Medicine
Abercrombie & Fitch Endowed Chair in Inflammatory Bowel Disease
Medical Director, OSU Inflammatory Bowel Disease Center
Program Director, Advanced Inflammatory Bowel Disease Fellowship
Division of Gastroenterology, Hepatology, and Nutrition
The Ohio State University Wexner Medical Center
Columbus, Ohio
Nana Bernasko, DNP, CRNP, WHNP-BC
Assistant Professor
Division of Gastroenterology and Hepatology
Department of Medicine
Penn State University Medical Center
Hershey, Pennsylvania
Richard H. Davis, PA-C
Senior Physician Assistant
Division of Gastroenterology, Hepatology, and Nutrition
University of Florida College of Medicine
Gainesville, Florida
The content in this series was adapted from a live CE program supported by educational grants from Amgen, Ferring Pharmaceuticls, Inc., and the Leona M. and Harry B. Helmsley Charitable Trust.
To access the full program, go to
pce.is/IBD
This podcast is the last in a series of four featuring IBD Dr Nana Bernasko, DNP, CRNP, WHNP-BC. In this episode, Dr Bernasko reviews the best practices for collaborating with primary care for optimal health maintenance in IBD patients, including cancer screening, bone health, immunizations, and more.
Presenter:
Nana Bernasko, DNP, CRNP, WHNP-BC
Assistant Professor
Division of Gastroenterology and Hepatology
Department of Medicine
Penn State University Medical Center
Hershey, Pennsylvania
The content in this series was adapted from a live CE program supported by educational grants from Amgen, Ferring Pharmaceuticals, Inc., and the Leona M. and Harry B. Helmsley Charitable Trust.
To access the full program, go to
pce.is/IBD
This podcast is the third in a series of four featuring IBD specialists Drs Anita Afzali, MD, MPH, FACG, AGAF and Nana Bernasko, DNP, CRNP, WHNP-BC. In this episode, our panel of experts review strategies for individualizing care, medication response challenges, the use of therapeutic drug monitoring, and treatment de-escalation strategies.
Presenters:
Anita Afzali, MD, MPH, FACG, AGAF
Professor of Clinical Medicine
Abercrombie & Fitch Endowed Chair in Inflammatory Bowel Disease
Medical Director, OSU Inflammatory Bowel Disease Center
Program Director, Advanced Inflammatory Bowel Disease Fellowship
Division of Gastroenterology, Hepatology, and Nutrition
The Ohio State University Wexner Medical Center
Columbus, Ohio
Nana Bernasko, DNP, CRNP, WHNP-BC
Assistant Professor
Division of Gastroenterology and Hepatology
Department of Medicine
Penn State University Medical Center
Hershey, Pennsylvania
The content in this series was adapted from a live CE program supported by educational grants from Amgen, Ferring Pharmaceuticals, Inc., and the Leona M. and Harry B. Helmsley Charitable Trust.
To access the full program, go to
pce.is/IBD
In this second of two podcasts, 2 experts in migraine provide clinical pearls focused on preventing migraine. Listen as they discuss patient factors that indicate preventive treatment is warranted, the range of available preventive treatments and their use in practice, and strategies for engaging patients in their care.
This activity is available for CE/CME credit. Claim your credit at pce.is/migraine.
Contributors:
Karen A. Williams, DNP, FNP-BC, AQH
President
KDW Health Management
Pensacola, Florida
Dr Williams: consultant/advisor/speaker: Biohaven.
Maureen Moriarty, DNP, ANP-BC
Associate Professor
Director
Malek School of Nursing Professions
Marymount University
Arlington, Virginia
Owner
Moriarty Associates
Westminster, Maryland
Dr Moriarty: consultant/advisor/speaker: AbbVie/Allergan, Amgen, Biohaven, Lilly; researcher: Teva.
In this first of two podcasts, 2 experts in migraine provide valuable information on the differential diagnosis of migraine, including screening tools and techniques to incorporate into your practice. Additionally, they detail acute treatment options ranging from nonpharmacologic to over-the-counter to novel prescription pharmacologic therapies and discuss their use in the acute migraine management paradigm. This activity is available for CE/CME credit. Claim your credit at pce.is/migraine.
Contributors:
Karen A. Williams, DNP, FNP-BC, AQH
President
KDW Health Management
Pensacola, Florida
Dr Williams: consultant/advisor/speaker: Biohaven.
Maureen Moriarty, DNP, ANP-BC
Associate Professor
Director
Malek School of Nursing Professions
Marymount University
Arlington, Virginia
Owner
Moriarty Associates
Westminster, Maryland
Dr Moriarty: consultant/advisor/speaker: AbbVie/Allergan, Amgen, Biohaven, Lilly; researcher: Teva.
In this first of two podcasts, 2 experts discuss risk factors and current recommendations for the diagnostic workup of ITP, and share strategies for initial management of newly diagnosed disease. Topics including corticosteroid overuse, approaches to improve remission rates, and contemporary concerns with COVID vaccination will be covered.. This activity is available for CE/CME credit. Claim your credit at pce.is/ITP.
Contributors:
Hanny Al-Samkari, MD
Assistant Professor
Harvard Medical School
Attending Hematologist and Clinical Investigator
Division of Hematology Oncology
Massachusetts General Hospital
Boston, Massachusetts
Christopher Nelson, ACNP-BC, MBA
Nurse Practitioner
Hematology and Oncology
Avera Cancer Institute
Avera St Luke’s Hospital
Aberdeen, South Dakota
Dr Al-Samkari: consultant/advisor/speaker: Argenx, Forma, Moderna, Novartis, Rigel; consultant/research funding (paid to institution): Agios, Amgen, Dova/Sobi.
Mr Nelson: consultant/advisor/speaker: Amgen, AbbVie, AstraZeneca, Bristol-Myers Squibb/Celgene, Beigene, Incyte, Karyopharm, Rigel, Sanofi.
In this second of two podcasts, listen as 2 experts discuss novel therapies that target disease pathophysiology, with a focus on individualizing treatment to optimize outcomes for their patients with ITP. Unique considerations of the drug and surgical options are discussed. This activity is available for CE/CME credit. Claim your credit at pce.is/ITP.
Contributors:
Hanny Al-Samkari, MD
Assistant Professor
Harvard Medical School
Attending Hematologist and Clinical Investigator
Division of Hematology Oncology
Massachusetts General Hospital
Boston, Massachusetts
Christopher Nelson, ACNP-BC, MBA
Nurse Practitioner
Hematology and Oncology
Avera Cancer Institute
Avera St Luke’s Hospital
Aberdeen, South Dakota
Dr Al-Samkari: consultant/advisor/speaker: Argenx, Forma, Moderna, Novartis, Rigel; consultant/research funding (paid to institution): Agios, Amgen, Dova/Sobi.
Mr Nelson: consultant/advisor/speaker: Amgen, AbbVie, AstraZeneca, Bristol-Myers Squibb/Celgene, Beigene, Incyte, Karyopharm, Rigel, Sanofi.
In this second of 2 podcasts episodes on the management of painful vaso-occlusive crises in patients with sickle cell disease, listen to Alison Towerman, RN, MSN, CPNP, and Michael R. DeBaun, MD, MPH, discuss available treatment options for the prevention of painful vaso-occlusive events, and provide emergency department and outpatient setting recommendations on the proper use and indications for hydroxyurea, L-glutamine, and P-selecting blocking antibody crizanlizumab. This activity is available for 0.25 ANCC and 0.25 AAPA credits, with 0.25 credits applicable for pharmacology credit for NPs. To receive credit for this program, go to pce.is/sickle.
Contributors:
Michael R. DeBaun, MD, MPH
Director
Vanderbilt-Meharry Center for Excellence in Sickle Cell Disease
Professor
Pediatrics and Medicine
Vice Chair for Clinical and Translational Research
Department of Pediatrics
J.C. Peterson Chair in Pediatrics
Nashville, Tennessee
Michael R. DeBaun, MD, MPH: consulting, speaker, and advisory board fees: Forma, GBT, Novartis, and Vertix.
Alison Towerman, RN, MSN, CPNP
Pediatric Nurse Practitioner
Department of Pediatrics, Division of Hematology/Oncology
Washington University School of Medicine in St. Louis
St. Louis, Missouri
Ms. Towerman has no relevant financial relationships to disclose.
In this first of 2 podcasts episodes, Alison Towerman, RN, MSN, CPNP, and Michael R. DeBaun, MD, MPH, discuss best practices for the management of painful vaso-occlusive crises (VOCs) in patients with sickle cell disease, review the disease pathophysiology, and provide emergency department and outpatient setting recommendations on nonpharmacologic and pharmacologic management of painful VOCs. This activity is available for 0.25 ANCC and 0.25 AAPA credits, with 0.25 credits applicable for pharmacology credit for NPs. To receive credit for this program, go to pce.is/sickle.
Contributors:
Michael R. DeBaun, MD, MPH
Director
Vanderbilt-Meharry Center for Excellence in Sickle Cell Disease
Professor
Pediatrics and Medicine
Vice Chair for Clinical and Translational Research
Department of Pediatrics
J.C. Peterson Chair in Pediatrics
Nashville, Tennessee
Michael R. DeBaun, MD, MPH: consulting, speaker, and advisory board fees: Forma, GBT, Novartis, and Vertix.
Alison Towerman, RN, MSN, CPNP
Pediatric Nurse Practitioner
Department of Pediatrics, Division of Hematology/Oncology
Washington University School of Medicine in St. Louis
St. Louis, Missouri
Ms. Towerman has no relevant financial relationships to disclose.
In this second of two podcasts, two oncologists discuss subsequent therapy for metastatic colorectal cancer, and review cases of patients with metastatic colorectal cancer to discuss testing for mutations and biomarkers, appropriate selection of treatment regimens, and management. This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU.
Contributors:
Joleen Hubbard MD
Cathy Eng, MD
Stephanie Andrews, MS, APRN-C
Ms Andrews: fees for non-CME/CE services: Genentech.
Dr Eng: consulting fees: Amgen, GlaxoSmithKline, Hoopika, Natera; contracted research (paid to institution): Merck, Pfizer.
Dr Hubbard: advisor: BeiGene; advisor/researcher: Bayer, Boston Biomedical, G1 Therapeutics, Hutchison MediPharma, Incyte, Merck, Pionyr Immunotherapeutics, Seagen, Senhwa Pharmaceuticals, Roche, Treos Bio, TriOncology, Trovogene.
In this first of two podcasts, oncologists discuss the latest evidence that informs how they select first-line treatment regimens for patients with metastatic colorectal cancer. Using cases for a patient-centered approach, they explore the recommended testing for mutations and biomarkers that impact metastatic colorectal cancer, how to plan strategies for incorporating novel agents into the treatment of patients and recommended strategies to identify and manage toxicities of novel agents for metastatic colorectal cancer. This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU.
Contributors:
Joleen Hubbard MD
Cathy Eng, MD
Stephanie Andrews, MS, APRN-C
Ms Andrews: fees for non-CME/CE services: Genentech.
Dr Eng: consulting fees: Amgen, GlaxoSmithKline, Hoopika, Natera; contracted research (paid to institution): Merck, Pfizer.
Dr Hubbard: advisor: BeiGene; advisor/researcher: Bayer, Boston Biomedical, G1 Therapeutics, Hutchison MediPharma, Incyte, Merck, Pionyr Immunotherapeutics, Seagen, Senhwa Pharmaceuticals, Roche, Treos Bio, TriOncology, Trovogene.
In this podcast, Dr. Alicia Morgans discusses recent data presented at the 2022 ASCO GU Cancers Symposium, including trials evaluating the use of first-line PARP inhibitors in combination with abiraterone for mCRPC, continuation of enzalutamide after progression, and imaging modalities as predictive and prognostic biomarkers. This activity is available for CE/CME credit. Claim your credit at pce.is/ascogu.
Contributors:
Dr Morgans has disclosed that she has received funds for research support from Atellas, AstraZeneca, Bayer, Myovant, and Pfizer, and consulting fees from AAA, Astellas, AstraZeneca, Bayer, Blue Earth, Clovis, Dendreon, Janssen, Lantheus, Merck, Myovant, Novartis, Pfizer, Sanofi, and Telix.
Ms Martone has no relevant conflicts of interest to report.
In this second of two podcasts, an expert discuss decision making for subsequent line therapy for advanced gastric cancer, and review cases to illustrate practical considerations, followed by a question-and-answer session. This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU.
Contributor:
David Ilson, MD
Dr Ilson: consulting fees: Aeris, Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Lilly, Merck, Roche, Taiho.
In this first of two podcasts, an expert discusses the data supporting their selection of first-line treatments for advanced gastric cancer. A case illustrates key takeaways about molecular markers that can impact choice of therapy in gastric cancer, novel and emerging treatments, and prevention and management of treatment-related toxicities. This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU.
Contributor:
David Ilson, MD
Dr Ilson: consulting fees: Aeris, Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Lilly, Merck, Roche, Taiho.
In this second episode of two podcasts, Dr. Amit Singal and Dr. Mark Yarchoan discuss how to identify, prevent and mitigate treatment-related adverse events, and review cases with careful considerations for patient-specific factors guiding treatment selection, followed by a question-and-answer session on the management of patients with HCC. This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU.
Contributors:
Amit Singal, MD, MS
Mark Yarchoan, MD
Bridget O’Brien, DNP, FNP-BC, AOCNP
Dr Singal: consulting fees: AstraZeneca, Bayer, Bristol-Myers Squibb, Eisai, Exelixis, Genentech, Roche.
Dr Yarchoan: consulting fees: AstraZeneca, Eisai, Exelixis, Genentech; other financial or material support: Bristol-Myers Squibb, Incyte.
Dr O’Brien: fees for non-CME/CE services: Amgen, Novartis.
In this first episode of two podcasts, Dr. Amit Singal and Dr. Mark Yarchoan discuss the latest data supporting their approach to selecting treatment regimens for patients with HCC, with topics including: the current challenges in the management of HCC, recommended initial workup strategies and the evolving treatment landscape in HCC. This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU.
Contributors:
Amit Singal, MD, MS
Mark Yarchoan, MD
Bridget O’Brien, DNP, FNP-BC, AOCNP
Dr Singal: consulting fees: AstraZeneca, Bayer, Bristol-Myers Squibb, Eisai, Exelixis, Genentech, Roche.
Dr Yarchoan: consulting fees: AstraZeneca, Eisai, Exelixis, Genentech; other financial or material support: Bristol-Myers Squibb, Incyte.
Dr O’Brien: fees for non-CME/CE services: Amgen, Novartis.
In this second of two podcasts, discuss the management of advanced urothelial cancer with novel therapies and how to address adverse events, and concludes the episode with a review of audience questions and patient cases. This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU.
Contributors:
Arjun Balar, MD
Rana R. McKay, MD
Terran W. Sims, MSN, ACNP-C, CNN-BC, COCN
Dr Balar: consulting fees: Bristol-Myers Squibb, Incyte, Istari Oncology, Janssen, Pfizer; consulting fees/research support: Immunomedics, Seagen; consulting fees/contracted research/fees for non-CME/CE services: AstraZeneca/Medimmune, Genentech; Merck; consulting fees/contracted research: Immunomedics/Gilead, Nektar, Seagen; consulting/ownership interest: EpiVax Oncology, GT Biopharma.
Dr McKay: consulting fees: AstraZeneca, Bristol-Myers Squibb, Calithera, Caris, Dendreon, Exelixis, Janssen, Merck, Myovant, Novarits, Sanofi, Sorrento Therapeutics; Vividion Therapeutics; consulting fees/contracted research: Bayer, Pfizer, Tempus.
Ms Sims: consulting fees: Coloplast.
In this first of two podcasts, expert faculty review the latest data on the management of advanced urothelial cancer with novel therapies including immune checkpoint inhibitors and antibody-drug conjugates. This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU.
Contributors:
Arjun Balar, MD
Terran W. Sims, MSN, ACNP-C, CNN-BC, COCN
Dr Balar: consulting fees: Bristol-Myers Squibb, Incyte, Istari Oncology, Janssen, Pfizer; consulting fees/research support: Immunomedics, Seagen; consulting fees/contracted research/fees for non-CME/CE services: AstraZeneca/Medimmune, Genentech; Merck; consulting fees/contracted research: Immunomedics/Gilead, Nektar, Seagen; consulting/ownership interest: EpiVax Oncology, GT Biopharma.
Ms Sims: consulting fees: Coloplast.
In this first of two podcasts, Dr. Rana R. McKay discusses the optimal treatment selection and management of adverse events for patients with metastatic and nonmetastatic castration-sensitive prostate cancer (CRPC), including the use of taxanes, androgen receptor agonists, and other therapies.
This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU.
Contributors:
Arjun Balar, MD
Rana R. McKay, MD
Terran W. Sims, MSN, ACNP-C, CNN-BC, COCN
Dr Balar: consulting fees: Bristol-Myers Squibb, Incyte, Istari Oncology, Janssen, Pfizer; consulting fees/research support: Immunomedics, Seagen; consulting fees/contracted research/fees for non-CME/CE services: AstraZeneca/Medimmune, Genentech; Merck; consulting fees/contracted research: Immunomedics/Gilead, Nektar, Seagen; consulting/ownership interest: EpiVax Oncology, GT Biopharma.
Dr McKay: consulting fees: AstraZeneca, Bristol-Myers Squibb, Calithera, Caris, Dendreon, Exelixis, Janssen, Merck, Myovant, Novarits, Sanofi, Sorrento Therapeutics; Vividion Therapeutics; consulting fees/contracted research: Bayer, Pfizer, Tempus.
Ms Sims: consulting fees: Coloplast.
In this second of two podcasts, Rana R. McKay, MD, and Arjun Balar, MD, and moderator Terran W. Sims, MSN, ACNP-C, CNN-BC, COCN, discuss the optimal treatment selection and management of adverse events for patients with metastatic and nonmetastatic castration-resistant or castration-sensitive prostate cancers, including the use of taxanes, androgen receptor agonists, and other therapies.
This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU.
Contributor:
Arjun Balar, MD
Rana R. McKay, MD
Terran W. Sims, MSN, ACNP-C, CNN-BC, COCN
Dr Balar: consulting fees: Bristol-Myers Squibb, Incyte, Istari Oncology, Janssen, Pfizer; consulting fees/research support: Immunomedics, Seagen; consulting fees/contracted research/fees for non-CME/CE services: AstraZeneca/Medimmune, Genentech; Merck; consulting fees/contracted research: Immunomedics/Gilead, Nektar, Seagen; consulting/ownership interest: EpiVax Oncology, GT Biopharma.
Dr McKay: consulting fees: AstraZeneca, Bristol-Myers Squibb, Calithera, Caris, Dendreon, Exelixis, Janssen, Merck, Myovant, Novarits, Sanofi, Sorrento Therapeutics; Vividion Therapeutics; consulting fees/contracted research: Bayer, Pfizer, Tempus.
Ms Sims: consulting fees: Coloplast.
In this first of two podcasts, Tracey M. Piparo, PA-C and Martin C. Mahoney, MD, PhD discuss the benefits of pneumococcal vaccination, review the types of pneumococcal vaccines currently available, and provide ACIP’s recently updated age-based and risk-based recommendations on when to use the new conjugated pneumococcal vaccines. This activity is available for CE/CME credit. Claim your credit at pce.is/pneu.
Contributors:
Martin C. Mahoney, MD, PhD
Professor
Department of Epidemiology and Environmental Health
University of Buffalo
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York
Dr Mahoney: consulting fees: Pfizer; consulting fees/fees for non-CME/CE services: Merck; fees for non-CME/CE services: GlaxoSmithKline, Sanofi.
Tracey M. Piparo, PA-C
Palliative Medicine
RWJ Barnabas Health
New Brunswick, New Jersey
Immediate Past President
New Jersey State Society of Physician Assistants
Ms. Piparo has no relevant financial relationships to disclose.
In this second of two podcasts, Tracey M. Piparo, PA-C and Martin C. Mahoney, MD, PhD discuss barriers to pneumococcal vaccination, especially in the younger risk-based population, and provide specific strategies providers can implement to help improve pneumococcal vaccination coverage rates in effort to decrease the burden of pneumococcal disease. This activity is available for CE/CME credit. Claim your credit at pce.is/pneu.
Contributor:
Martin C. Mahoney, MD, PhD
Professor
Department of Epidemiology and Environmental Health
University of Buffalo
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York
Dr Mahoney: consulting fees: Pfizer; consulting fees/fees for non-CME/CE services: Merck; fees for non-CME/CE services: GlaxoSmithKline, Sanofi.
Tracey M. Piparo, PA-C
Palliative Medicine
RWJ Barnabas Health
New Brunswick, New Jersey
Immediate Past President
New Jersey State Society of Physician Assistants
Ms. Piparo has no relevant financial relationships to disclose.
In this second of 2 podcasts, Tracey Piparo, PA-C and Martin C. Mahoney, MD, PhD provide strategies to overcome HPV vaccination barriers to improve our HPV vaccination rates among eligible individuals. The podcast includes a discussion of both provider and patient/caregiver barriers as well as specific strategies you can implement, including use of shared-decision making, to help prevent HPV-associated cancers through higher HPV vaccination rates. This activity is available for CE/CME credit. Claim your credit at pce.is/hpv.
Martin C. Mahoney, MD, PhD
Professor
Department of Epidemiology and Environmental Health
University of Buffalo
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York
Dr Mahoney: consulting fees: Pfizer; consulting fees/fees for non-CME/CE services: Merck; fees for non-CME/CE services: GlaxoSmithKline, Sanofi.
Tracey M. Piparo, PA-C
Palliative Medicine
RWJ Barnabas Health
New Brunswick, New Jersey
Immediate Past President
New Jersey State Society of Physician Assistants
Ms. Piparo has no relevant financial relationships to disclose.
Tune into this informative conversation between Tracey M. Piparo, PA-C and Martin C. Mahoney, MD, PhD regarding the appropriate use of HPV vaccines for prevention of HPV-related cancers. Topics covered in this podcast include an overview of the burden of HPV, HPV vaccination coverage rates across different age groups, eligibility for HPV vaccination, and age-based dosing schedules. This activity is available for CE/CME credit. Claim your credit at pce.is/hpv.
Contributors:
Martin C. Mahoney, MD, PhD
Professor
Department of Epidemiology and Environmental Health
University of Buffalo
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York
Dr Mahoney: consulting fees: Pfizer; consulting fees/fees for non-CME/CE services: Merck; fees for non-CME/CE services: GlaxoSmithKline, Sanofi.
Tracey M. Piparo, PA-C
Palliative Medicine
RWJ Barnabas Health
New Brunswick, New Jersey
Immediate Past President
New Jersey State Society of Physician Assistants
Ms. Piparo has no relevant financial relationships to disclose.
In this second of two podcasts, hear Dr Robin Dore discuss key information from ACR Convergence 2021, including the use of COVID-19 vaccine in immunosuppressed adults with autoimmune diseases; the cardiovascular risk of hydroxychloroquine in rheumatoid arthritis; whether the boxed warning for romosozumab helps prevent inappropriate use in postmenopausal women with osteoporosis and a history of myocardial infarction or stroke; how the incidence of cardiovascular events in patients with rheumatoid arthritis compares with that of patients with diabetes; and evaluating the risk of mortality in patients with suboptimally treated gout. This activity is available for CE/CME credit. Claim your credit at pce.is/ACR.
In this first of two podcasts, hear Dr Vibeke Strand discuss key information from ACR Convergence 2021, including the potential to intervene in patients who are at high risk for developing rheumatoid arthritis; whether vitamin D3 and n-3 fatty acids can prevent autoimmune disease; the Food and Drug Administration’s perspective on the safety of Janus kinase inhibitors; and results from a phase 3b/4 randomized safety study of tofacitinib vs tumor necrosis factor inhibitors. This activity is available for CE/CME credit. Claim your credit at pce.is/ACR.
In this second of 2 podcasts, Tish Haight, ACNP, CCRN, BC, and January-Jill Ogoy, DHSc, MPA, PA-C, provide clinical perspective on selected practice changing abstracts, covering a variety of topics from the CHEST 2021 Annual Meeting. Topics covered in this podcast include a chronic cough treatment in the pipeline, inhaled corticosteroid use and COVID-19 outcomes, and paradoxical bronchospasm with short-acting beta 2-agonists.. This activity is available for CE/CME credit. Claim your credit at pce.is/CHEST.
Contributors:
Tish Haight, ACNP, CCRN, BC
Pulmonary, Critical Care
Lung Associates of Sarasota
Sarasota, FL
Ms. Haight has no relevant financial relationships to disclose.
January-Jill Ogoy, DHSc, MPA, PA-C
APC, Pulmonary and Critical Care Medicine
Virginia Mason Franciscan Health
Tacoma, WA
Dr. Ogoy has no relevant financial relationships to disclose.
In this first of 2 podcasts, Tish Haight, ACNP, CCRN, BC, and January-Jill Ogoy, DHSc, MPA, PA-C, provide clinical perspective on selected practice changing abstracts, covering a variety of topics from the CHEST 2021 Annual Meeting. Topics covered in this podcast include a comparison of idiopathic pulmonary arterial hypertension outcomes, an evaluation of combination therapies for the treatment of COPD, and the use of CPAP in patients hospitalized with COVID-19 pneumonitis. This activity is available for CE/CME credit. Claim your credit at pce.is/CHEST.
Contributors:
Tish Haight, ACNP, CCRN, BC
Pulmonary, Critical Care
Lung Associates of Sarasota
Sarasota, FL
Ms. Haight has no relevant financial relationships to disclose.
January-Jill Ogoy, DHSc, MPA, PA-C
APC, Pulmonary and Critical Care Medicine
Virginia Mason Franciscan Health
Tacoma, WA
Dr. Ogoy has no relevant financial relationships to disclose.
In this podcast, an expert offers his perspective on the role of newer agents in atopic dermatitis—when they’re indicated, how to use them, where they fit on the therapeutic ladder, and adverse effects to monitor for. Also, tips on how to individualize therapy and anticipate adherence issues. The podcast concludes with thoughts on how to address some frequently-asked questions from patients and caregivers. This activity is available for CE/CME credit. Claim your credit at pce.is/AD.
Contributors:
Robert Sidbury, MD, MPH
Chief
Division of Dermatology
Seattle Children's Hospital
Professor
Department of Pediatrics
University of Washington School of Medicine
Seattle, Washington
Morgan Maier, PA-C, BS
Physician Assistant
Division of Dermatology
Seattle Children's Hospital
Seattle, Washington
Targeted therapies address the underlying pathways that cause airflow obstruction in patients with asthma, including a number of biologic therapies that have been approved. Omalizumab targets IgE (approved for moderate to severe persistent asthma). Three agents target IL-5, which plays a key role in the activation of eosinophils, and are approved for severe eosinophilic asthma: mepolizumab, reslizumab, and benralizumab. Dupilumab targets IL-4/13 and has been approved for moderate to severe eosinophilic asthma or patients requiring maintenance OCS. All agents are available as subcutaneous injections administered at specific intervals, with the exception of reslizumab, which is available as an intravenous infusion. Selection of which biologic agent to use is dependent on multiple factors, including cost, dosing frequency, delivery route, and patient preference among other considerations. The GINA guidelines suggest a biologic agent should be given a trial of at least 4 months; if treatment response is unclear, clinicians should consider extending the trial another 6 to 12 months. If no response is noted, therapy should be changed to another biologic agent. These biologic therapies are generally safe and well tolerated; however, primary care clinicians seeing patients with asthma must be knowledgeable about common adverse events in order to recognize them.
Claim your credit here:
https://bit.ly/3pDx3NI
Contributors:
Lawrence Herman, DMSc, MPA, PA-C
Adjunct Faculty
Doctor of Medical Science Program
University of Lynchburg School of PA Medicine
Lynchburg, Virginia
President
Palantir Healthcare, LLC
Boiling Springs, South Carolina
Samuel Louie, MD
Professor Emeritus
Division of Pulmonary and Critical Care Medicine
University of California, Davis
Davis, California
Asthma is now recognized as a heterogeneous, multidimensional disease that involves numerous pathophysiologic factors, including bronchiolar inflammation with airway constriction and resistance. The identification of distinct patient populations (phenotypes/endotypes) is increasingly being recognized as an important strategy for optimizing the management of patients with asthma. Asthma phenotype is based on clinical symptoms such as respiratory function, onset age, and blood biochemical examination values.
Clinical studies have shown that asthma phenotypes have specific patterns of inflammation that require different treatment approaches. For example, eosinophilic asthma is characterized by airway and systemic markers of eosinophilia, subepithelial fibrosis, and corticosteroid responsiveness, whereas non-eosinophilic asthma is characterized by the absence of eosinophilia and subepithelial fibrosis, as well as poor responsiveness to corticosteroids. In addition to high immunoglobulin (Ig) E levels in up to 60% of patients, asthma is characterized by tissue eosinophilia, which is mediated in part by interleukin (IL)-5. Because eosinophils produce inflammatory proteins that lead to tissue damage, the eosinophilic phenotype of asthma is associated with greater symptom severity, increased risk of exacerbation, and decreased lung function. The GINA guidelines recommend that asthma should be classified by phenotype, especially when it becomes difficult to treat or refractory to treatment.
Claim your credit here:
https://bit.ly/3vUN7Mo
Contributors:
Lawrence Herman, DMSc, MPA, PA-C
Adjunct Faculty
Doctor of Medical Science Program
University of Lynchburg School of PA Medicine
Lynchburg, Virginia
President
Palantir Healthcare, LLC
Boiling Springs, South Carolina
Samuel Louie, MD
Professor Emeritus
Division of Pulmonary and Critical Care Medicine
University of California, Davis
Davis, California
An early, accurate diagnosis and appropriate pharmacologic and nonpharmacologic treatment of IPF are imperative for improved outcomes. Given the poor prognosis of IPF, educating and involving patients in their care is necessary for optimal quality of life.
In this podcast, Corinne R. Young, MSN, FNP-C, FCCP, provides an overview of key points addressed by expert faculty during a live webinar. Please visit PCE.IS/ipf to view more activities on IPF.
Corinne R. Young, MSN, FNP-C, FCCP
Founder and President
Association of Pulmonary Advanced Practice Providers
Pulmonary Nurse Practitioner
Colorado Springs, Colorado
Effective influenza management during the COVID-19 pandemic requires a knowledge of emerging diagnostics, immunizations, and antiviral agents. The armamentarium for influenza treatment now includes multiple classes including neuraminidase inhibitors (eg, oseltamivir) and the polymerase acidic endonuclease inhibitor, baloxavir. In this podcast, Mary Knudtson, DNSc, NP, FAAN, asks questions from healthcare professionals to infectious disease expert, Michael G. Ison, MD, MS on timely, individualized influenza prevention and treatment. This activity is available for CE/CME credit. Claim your credit at pce.is/flu.
Influenza management continues to increase in complexity as new diagnostic, prevention, and treatment options emerge and the COVID-19 pandemic adds additional considerations. Antiviral therapies for influenza now include neuraminidase inhibitors (eg, oseltamivir) and baloxavir. In this podcast, Lawrence Herman, DMSc, MPA, PA-C, asks timely influenza questions from healthcare professionals to infectious disease expert, Tracy Zivin-Tutela, MD. This activity is available for CE/CME credit. Claim your credit at pce.is/flu.
In the global effort to address the COVID-19 pandemic, healthcare practitioners need to stay up to date as the Emergency Use Authorization (EUAs) for treatments and vaccines change rapidly. This 6-part podcast series opens with a discussion of how EUAs work and how they are different from full approval. In the subsequent episodes, experts explain the latest evidence-based information on inpatient and outpatient antiviral treatments, the most recent information on available vaccines, and how the emerging SARS-CoV-2 variants impact our COVID-19 toolbox.In this last episode of the 6-part series, an expert describes what is known about the SARS-CoV-2 variants—including the UK, South African, and Brazilian variants that are becoming more prevalent in the United States. The discussion then focuses on how these variants impact the efficacy of vaccines and monoclonal antibodies. Claim your credit at pce.is/COV19.
In the global effort to address the COVID-19 pandemic, healthcare practitioners need to stay up to date as the Emergency Use Authorization (EUAs) for treatments and vaccines change rapidly. This 6-part podcast series opens with a discussion of how EUAs work and how they are different from full approval. In the subsequent episodes, experts explain the latest evidence-based information on inpatient and outpatient antiviral treatments, the most recent information on available vaccines, and how the emerging SARS-CoV-2 variants impact our COVID-19 toolbox.This episode provides an overview of the rapid development of vaccines currently under Emergency Use Authorization (EUA) for the prevention of SARS-CoV-2 in the United States. An expert describes the mechanisms of action for the mRNA and viral vector vaccines, as well as efficacy, side effects, and post-vaccine safety assessment. The conversation concludes with a review of what is needed to achieve herd immunity, and guidance for people who are fully vaccinated. Claim your credit at pce.is/COV19.
In the global effort to address the COVID-19 pandemic, healthcare practitioners need to stay up to date as the Emergency Use Authorization (EUAs) for treatments and vaccines change rapidly. This 6-part podcast series opens with a discussion of how EUAs work and how they are different from full approval. In the subsequent episodes, experts explain the latest evidence-based information on inpatient and outpatient antiviral treatments, the most recent information on available vaccines, and how the emerging SARS-CoV-2 variants impact our COVID-19 toolbox.In this fourth episode of the 6-part series, an expert explains what COVID-19 treatments are available in the outpatient setting. The focus is on monoclonal antibodies, bamlanivimab + etesevimab and casirivimab + imdevimab. For both drug combinations, he discusses the Emergency Use Authorization (EUA) indications, evidence on efficacy, and potential toxicities. Claim your credit at pce.is/COV19.
In the global effort to address the COVID-19 pandemic, healthcare practitioners need to stay up to date as the Emergency Use Authorization (EUAs) for treatments and vaccines change rapidly. This 6-part podcast series opens with a discussion of how EUAs work and how they are different from full approval. In the subsequent episodes, experts explain the latest evidence-based information on inpatient and outpatient antiviral treatments, the most recent information on available vaccines, and how the emerging SARS-CoV-2 variants impact our COVID-19 toolbox.In this second half of a discussion about treatments for COVID-19 in the hospital setting, an expert explains the use of dexamethasone, including insights on the choice of steroids to treat COVID-19 in pregnancy. The conversation then moves to other immune modulators, tocilizumab and the combination of baricitinib plus the antiviral remdesivir, and includes an overview of the evidence on efficacy and safety.Claim your credit at pce.is/COV19.
In the global effort to address the COVID-19 pandemic, healthcare practitioners need to stay up to date as the Emergency Use Authorization (EUAs) for treatments and vaccines change rapidly. This 6-part podcast series opens with a discussion of how EUAs work and how they are different from full approval. In the subsequent episodes, experts explain the latest evidence-based information on inpatient and outpatient antiviral treatments, the most recent information on available vaccines, and how the emerging SARS-CoV-2 variants impact our COVID-19 toolbox.This episode is the first half of an expert discussion on treatments for COVID-19 in the hospital setting. The episode covers the latest information on the use of convalescent plasma and remdesivir, including the available efficacy data, when to administer treatment, and potential toxicities to expect.Claim your credit at pce.is/COV19.
In the global effort to address the COVID-19 pandemic, healthcare practitioners need to stay up to date as the Emergency Use Authorization (EUAs) for treatments and vaccines change rapidly. This 6-part podcast series opens with a discussion of how EUAs work and how they are different from full approval. In the subsequent episodes, experts explain the latest evidence-based information on inpatient and outpatient antiviral treatments, the most recent information on available vaccines, and how the emerging SARS-CoV-2 variants impact our COVID-19 toolbox. This activity is available for CE/CME credit.
In this first of a 6-episode series on Emergency Use Authorization (EUA) in COVID-19, an expert explains the differences between EUA and full approval, how long EUAs last, and how new clinical trial evidence supports and changes an EUA. The discussion concludes with an overview of safety and management of potential adverse events. Claim your credit at pce.is/COV19.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are now firmly established as guideline-recommended antiglycemic agents of choice in patients with type 2 diabetes, especially when comorbid disease is evident or when the patient is at high risk for such conditions. Join Davida Kruger, NP and Anne Peters, MD for a lively discussion on the use of GLP-1 RAs in clinical practice, including how to use shared decision-making to choose an ideal agent based on patient, disease, and GLP-1 RA characteristics. The unique effects of GLP-1 RAs on cardiovascular disease and weight mitigation are also discussed in the context of patient selection and management.
This episode is available for CE/CME credit.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are now firmly established as guideline-recommended antiglycemic agents of choice in patients with type 2 diabetes, especially when comorbid disease is evident or when the patient is at high risk for such conditions. In this second of two podcasts, Davida Kruger, NP and Anne Peters, MD share tips and pearls for treating patients with type 2 diabetes using GLP-1 RAs, including when to choose a GLP-1 RA, how to broach the topic of a first injectable, when an oral agent is preferred, strategies for encouraging lifestyle modifications, and practical advice on preparing and monitoring patients with respect to GLP1-RA therapy.
This episode is available for CE/CME credit.
A number of specific therapies are now available for pulmonary arterial hypertension (PAH), and the outlook for patients with PAH has never been better. But first PAH must be differentiated from the other forms of pulmonary hypertension. In this podcast, Corinne Young, FNP-C, president of the Association of Pulmonary Advanced Practice Providers, talks with pulmonary hypertension expert Martha Kingman, FNP-C, DNP, about establishing the diagnosis of PAH, determining the subcategory of PAH, today’s approach to management, and the important role of primary care NPs and PAs in long-term follow-up. This activity is available for CE/CME credit.
All pulmonary hypertension is not the same, and it’s important to differentiate among the five different subtypes to ensure effective management. In this podcast, Corinne Young, FNP-C, president of the Association of Pulmonary Advanced Practice Providers, talks with pulmonary hypertension expert Martha Kingman, FNP-C, DNP, about the classification system for pulmonary hypertension, how to distinguish the five subtypes clinically, and best practices in management. This episode is available for CE/CME credit.
In this episode, Karl Doghramji, MD, Medical Director at the Jefferson Sleep Disorders Center in Philadelphia, talks to clinicians about the newest class of pharmacologic agents, orexin receptor antagonists, for the treatment of insomnia. He also discusses how to recognize signs, symptoms, and risk factors that should trigger screening, differentiation of the different types of sleep disorders, and lifestyle measures that should be part of any treatment.
Primary care practitioners play a major role in the management of asthma, providing diagnosis, patient education, and management plans. But when the asthma remains uncontrolled, management can be challenging. On this podcast, Corinne Young FNP-C, president of the Association of Pulmonary Advanced Practice Providers speaks with asthma expert Ann Hefel, FNP-C of Children's Hospital Colorado about what clinicians have in their therapeutic toolbox to help patients with moderate to severe disease whose asthma remains uncontrolled despite adequate therapy. This activity is available for CE/CME credit.
As many as 20% of patients with asthma may not be achieving adequate control of their symptoms, even after they have maximized inhaled corticosteroids and their long-acting beta 2 agonist. If left uncontrolled, patients are at increased risk for serious exacerbations that can lead to ED visits and extended hospitalizations. In this podcast, Corinne Young, FNP-C, president of the Association of Pulmonary Advanced Practice Providers, talks with her colleague Ann Hefel, FNP, an allergy and asthma specialist from Children’s Hospital Colorado about reasons for poor asthma control and how to conduct an effective patient workup to identify the potential causes. This episode is available for CE/CME credits for NPs and PAs.
In this episode, Dr. Brooks Cash provides an expert look at chronic idiopathic constipation, how to differentiate it from a commonly confused condition, irritable bowel syndrome, and when diagnosed what treatment options are available, both nonpharmacologic and pharmacologic.
